RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Minerva Neurosciences Stock

Minerva Neurosciences ROCE 2024

Minerva Neurosciences ROCE

0.81

Ticker

NERV

ISIN

US6033801068

WKN

A1171S

In 2024, Minerva Neurosciences's return on capital employed (ROCE) was 0.81, a -35.6% increase from the 1.26 ROCE in the previous year.

Minerva Neurosciences Aktienanalyse

What does Minerva Neurosciences do?

Minerva Neurosciences was founded in 2007 and is a biopharmaceutical company focused on developing therapies for various psychiatric and neurological disorders. The company's business model is based on identifying promising molecules and developing them clinically until they are approved by health authorities. Minerva works closely with academic institutions and other partners to expand its pipeline of potential products. The company is focused on developing therapies for disorders such as schizophrenia, depression, sleep disorders, Parkinson's, and Alzheimer's. Minerva Neurosciences' main products are the antipsychotic MIN-101, targeting the treatment of schizophrenia, and the antidepressant MIN-117, developed for the treatment of depression. Both products are currently in clinical development and have the potential to offer new treatment options for patients. Furthermore, Minerva Neurosciences has entered into exclusive licensing agreements with other companies to develop innovative therapies for rare diseases. One of these products is the medication Roluperidone, which can be used for schizophrenic disorders. Minerva Neurosciences is divided into three business segments: Minerva Neurosciences Inc, Minerva Manufacturing Inc, and Minerva Therapeutics Inc. Minerva Manufacturing has its own research and development department and specializes in manufacturing clinical trial products. Minerva Therapeutics is a subsidiary focused on developing gene therapies for rare diseases. The company aims to improve the quality of life for patients with neurological and psychiatric disorders. Minerva Neurosciences pursues a strategy of collaborating with external partners and academic institutions to foster innovation and develop new therapies. Overall, Minerva Neurosciences has the potential to play a significant role in the treatment of central nervous system disorders and improve the health and well-being of millions of people worldwide. Minerva Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Minerva Neurosciences's Return on Capital Employed (ROCE)

Minerva Neurosciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Minerva Neurosciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Minerva Neurosciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Minerva Neurosciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Minerva Neurosciences stock

What is the ROCE (Return on Capital Employed) of Minerva Neurosciences this year?

The ROCE of Minerva Neurosciences is 0.81 undefined this year.

How has the ROCE (Return on Capital Employed) of Minerva Neurosciences developed compared to the previous year?

The ROCE of Minerva Neurosciences has increased by -35.6% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Minerva Neurosciences?

A high Return on Capital Employed (ROCE) indicates that Minerva Neurosciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Minerva Neurosciences?

A low ROCE (Return on Capital Employed) can indicate that Minerva Neurosciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Minerva Neurosciences impact the company?

An increase in the ROCE of Minerva Neurosciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Minerva Neurosciences affect the company?

A decrease in ROCE of Minerva Neurosciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Minerva Neurosciences?

Some factors that can affect Minerva Neurosciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Minerva Neurosciences so important for investors?

The ROCE of Minerva Neurosciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Minerva Neurosciences take to improve the ROCE?

To improve the ROCE, Minerva Neurosciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Minerva Neurosciences pay?

Over the past 12 months, Minerva Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Minerva Neurosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Minerva Neurosciences?

The current dividend yield of Minerva Neurosciences is .

When does Minerva Neurosciences pay dividends?

Minerva Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Minerva Neurosciences?

Minerva Neurosciences paid dividends every year for the past 0 years.

What is the dividend of Minerva Neurosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Minerva Neurosciences located?

Minerva Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Minerva Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Minerva Neurosciences from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Minerva Neurosciences pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Minerva Neurosciences in the year 2023?

In the year 2023, Minerva Neurosciences distributed 0 USD as dividends.

In which currency does Minerva Neurosciences pay out the dividend?

The dividends of Minerva Neurosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Minerva Neurosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Minerva Neurosciences

Our stock analysis for Minerva Neurosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Minerva Neurosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.